Internship

Quality Engineer

LivaNova

LivaNova

1,001-5,000 employees

Global cardiopulmonary and neuromodulation devices

No salary listed

Wheat Ridge, CO, USA

In Person

Category
QA & Testing
Requirements
  • Successfully demonstrates an in-depth or breadth of engineering skill(s).
  • Must have proficiency with quality tools such as flowcharts, statistical data analysis, mathematical reasoning.
  • Excellent communication (written and verbal) and presentation skills.
  • Able to communicate across functional lines.
  • Must be able to work in a clean room environment and tolerate chemical odors.
  • Must be able to work in a lab environment and tolerate the smell and sight of blood.
  • Strong verbal and written communication skills in English.
  • Pursuing a Bachelor Degree in Biomedical, Chemical or Mechanical Engineering, or other technical degree (computer science, chemistry, biochemistry, etc.), must have completed Junior year
  • Minimum GPA 3.0
Responsibilities
  • You will perform quality work of a broad nature to achieve successful outcomes of departmental and company objectives under guidance and oversight by the Quality Engineer.
  • You will assist Quality Engineering in completing tasks to ensure that production and process control activities are conducted in compliance with the company quality system and the international regulations governing medical device manufacturing and distribution.
  • You will help collect and analyze data for use by Quality Engineering in the evaluation of non-conforming products, product disposition and CAPAs to address quality issues.
  • You will also assist in general procedure updates required as part of process improvements and on-going maintenance of the Quality Management System.
Desired Qualifications
  • Any experience working with a medical device manufacturer including FDA regulations and ISO 13485 is desirable.

LivaNova focuses on cardiopulmonary and neuromodulation medical technologies, delivering devices and therapies for heart and brain conditions. Its products, used in hospitals worldwide, include implants and related treatments that aim to improve patient health while providing clinical and economic value to healthcare systems. The company differentiates itself with a diverse, integrated portfolio backed by decades of experience and a global reach, aligning clinical outcomes with economic impact. Its goal is to improve patients’ lives by delivering meaningful health benefits and helping providers achieve better value.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

2015

Your Connections

People at LivaNova who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Aura6000 FDA approval opens a large obstructive sleep apnea market.
  • CMS coverage for depression VNS could expand reimbursement and patient access.
  • China Essenz launch and Medicare reimbursement increases support near-term revenue growth.

What critics are saying

  • Third-party components constrain Essenz scaling, especially in China.
  • A $400 million litigation payment will pressure cash flow and margins.
  • FDA or CMS delays can stall obstructive sleep apnea and depression growth.

What makes LivaNova unique

  • LivaNova combines neuromodulation, cardiopulmonary, and obstructive sleep apnea programs.
  • Jette Nygaard-Andersen adds Coloplast governance and international medical device experience.
  • The Essenz platform plus Orrum analytics strengthens cardiopulmonary workflow differentiation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Employee Stock Purchase Plan

Flexible Work Hours

Paid Vacation

Company News

Business Wire
Mar 19th, 2026
LivaNova's aura6000 system gains FDA approval for moderate to severe obstructive sleep apnea treatment

LivaNova has received FDA premarket approval for its aura6000 System to treat adults with moderate to severe obstructive sleep apnea. The device uses proximal hypoglossal nerve stimulation for patients with an apnea-hypopnea index between 15 and 65 who cannot tolerate or have failed first-line therapies like positive airway pressure. The approval follows the OSPREY randomised controlled trial, which met its primary endpoints after six months. At 12 months, 65% of treatment patients achieved responder status, defined as at least 50% improvement from baseline and an AHI below 20. LivaNova is preparing a next-generation device for FDA submission featuring MRI compatibility, remote configuration and rechargeable battery technology lasting up to 15 years. The company plans to commercialise the advanced system next year.

Yahoo Finance
Feb 25th, 2026
LivaNova reports Q4 2025 results with fifth consecutive year of double-digit EPS growth

LivaNova, a medical device company, held its fourth-quarter and full-year 2025 earnings call, reporting strong financial performance. The company delivered double-digit revenue growth, expanded adjusted operating margins and generated robust cash flow across its cardiopulmonary and epilepsy businesses. CEO Vladimir Makatsaria highlighted that 2025 marked the company's fifth consecutive year of double-digit earnings per share growth and third straight year of double-digit organic revenue growth. The company also made progress towards financial targets outlined at its November investor day. The earnings call included executives Vladimir Makatsaria, Chief Financial Officer Alex Shvartsburg, Chief Innovation Officer Ahmet Tezel and Vice President of Investor Relations Briana Gotlin. The company posted a complementary presentation summarising key points on its investor relations website.

Yahoo Finance
Feb 25th, 2026
LivaNova posts third consecutive year of double-digit growth, targets 80% Essence heart-lung machine placements by 2026

LivaNova, a medical technology company, reported its third consecutive year of double-digit organic revenue growth in 2025, driven by its Essence heart-lung machine and cardiopulmonary consumables. The company has issued 2026 revenue guidance of 6% to 7% growth. LivaNova is transitioning focus towards high-margin markets including obstructive sleep apnea, with clinical trial device approval expected in the first half of 2026. The epilepsy business received a boost from a 48% Medicare reimbursement increase effective January 2026. The company strengthened its balance sheet by reducing debt from $628 million to $377 million. LivaNova expects to maintain adjusted operating margins above 20% whilst increasing R&D investment. A $400 million litigation payment is anticipated in the third quarter of 2026.

PR Newswire
Feb 20th, 2026
Orrum partners with LivaNova to integrate CŌRE Insights analytics with Essenz Perfusion System

Orrum Clinical Analytics has announced a strategic partnership with LivaNova USA to integrate its CŌRE Insights analytics platform with LivaNova's Essenz Perfusion System. The collaboration will enable automatic transfer of perfusion case data from Essenz to Orrum's platform for post-operative analysis and peer benchmarking. The integration, called CoreInsights for Essenz, allows perfusion teams to access continuous data capture, clinically relevant analytics measuring adherence to hospital and national benchmarks, and actionable insights on practice patterns and performance indicators. Built within a Patient Safety Organization recognised by the US Department of Health and Human Services, the platform provides secure data visualisation and analytics across the patient care continuum. The partnership aims to support evidence-based performance improvement in cardiopulmonary bypass patient management and extracorporeal care.

BioSpace
May 1st, 2024
Livanova Reports First-Quarter 2024 Results

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.Financial Summary and Highlights(1). First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 13.5% on a constant-currency basis. First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73